Key Points
- Director Fred Zeidman bought 12,500 shares of Bluejay Diagnostics at $2.00 per share, spending a total of $25,000 and increasing his direct stake to 12,500 shares.
- Bluejay Diagnostics stock was up 3.0% and opened at $1.72, with the company carrying a market cap of about $1.78 million and trading well below its 200-day average of $3.19.
- The company recently reported a quarterly EPS of ($1.95), while analysts currently rate the stock a consensus “Sell” and Weiss Ratings reiterated a “sell (e+)” view.
Bluejay Diagnostics, Inc. (NASDAQ:BJDX - Get Free Report) Director Fred Zeidman purchased 12,500 shares of Bluejay Diagnostics stock in a transaction on Saturday, March 14th. The stock was bought at an average price of $2.00 per share, for a total transaction of $25,000.00. Following the transaction, the director directly owned 12,500 shares in the company, valued at approximately $25,000. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Bluejay Diagnostics Trading Up 3.0%
NASDAQ BJDX opened at $1.72 on Tuesday. The business's 50-day moving average price is $1.90 and its two-hundred day moving average price is $3.19. Bluejay Diagnostics, Inc. has a 12 month low of $1.63 and a 12 month high of $16.68. The firm has a market capitalization of $1.78 million, a PE ratio of -0.15 and a beta of 0.72.
Bluejay Diagnostics (NASDAQ:BJDX - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 65,000 shares of the company's stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent filing with the SEC. 18.47% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Bluejay Diagnostics has a consensus rating of "Sell".
Get Our Latest Stock Report on Bluejay Diagnostics
Bluejay Diagnostics Company Profile
(
Get Free Report)
Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company's lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.
Leveraging a proprietary immunoassay platform, Bluejay's technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
